Alector to Present at the BofA Securities 2021 Virtual Health Care Conference

Rhea-AI Summary

Alector, a clinical-stage biotechnology company specializing in immuno-neurology, announced participation by its president and COO, Shehnaaz Suliman, in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on May 13, 2021, at 11:45 a.m. ET. A live webcast will be accessible on the Alector website, with a replay available for 30 days post-event. Alector focuses on innovative therapies for neurodegenerative diseases, emphasizing innate immune system repair and targeting genetic mutations in neurodegenerative conditions.

SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Shehnaaz Suliman, M.D., MBA, M.Phil., president and chief operating officer of Alector, will participate in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on Thursday, May 13, 2021, at 11:45 a.m. ET.

A live webcast of the fireside chat will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com. A replay will be available on the Alector website for 30 days following the event.

About Alector

Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. The Company is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The Company’s immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. This scientific approach is also the basis for the Company’s immuno-oncology programs. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com.

Contacts

1AB
Dan Budwick
973-271-6085
dan@1abmedia.com

or

Investors:
Alector, Inc.
ir@alector.com

FAQ

What is Alector's participation in the BofA Securities 2021 Virtual Health Care Conference?

Alector will have its president and COO, Shehnaaz Suliman, participate in a fireside chat on May 13, 2021, at 11:45 a.m. ET.

Where can I watch the Alector fireside chat live?

The live webcast of the Alector fireside chat will be available on the 'Events & Presentations' page in the Investors section of their website.

How long will the Alector fireside chat replay be available?

The replay of Alector's fireside chat will be available for 30 days following the event.

What is Alector's focus in biotechnology?

Alector specializes in immuno-neurology, developing therapies for neurodegenerative diseases by targeting immune dysfunction.

What diseases does Alector target with its treatments?

Alector's immuno-neurology candidates focus on frontotemporal dementia and Alzheimer’s disease.